The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Global Targeted Radionuclide Drug market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Targeted Radionuclide Drug market research.
Key companies engaged in the Targeted Radionuclide Drug industry include POINT Biopharma, Telix, ITM AG, Bayer AG, Novartis, Lantheus, Curium Pharma, Fusion Pharmaceuticals and RadioMedix, Inc., etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Targeted Radionuclide Drug were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Targeted Radionuclide Drug market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Targeted Radionuclide Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
- POINT Biopharma
- Telix
- ITM AG
- Bayer AG
- Novartis
- Lantheus
- Curium Pharma
- Fusion Pharmaceuticals
- RadioMedix, Inc.
- Convergent Therapeutics
- IONETIX
- Clarity Pharmaceuticals
- RayzeBio, Inc
- AmbioPharm
- Bracco Imaging
- Navidea
- China Isotope & Radiation Corporation
- Yantai Dongcheng
- Grand Pharma
- Hengrui Medicine
- Yunnan Baiyao Group
- SmartNuclide Biopharma
- Sinotau
- Hexin Pharmaceutical
Segment by Type
- Medicine
- Inhibitor
Segment by Application
- Tumors
- Thyroid
- Others
By Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Russia, Nordic Countries, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea,Southeast Asia, India, Australia, Rest of Asia)
- Latin America (Mexico, Brazil, Rest of Latin America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
The Targeted Radionuclide Drug report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Targeted Radionuclide Drug Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Medicine
1.2.3 Inhibitor
1.3 Market by Application
1.3.1 Global Targeted Radionuclide Drug Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Tumors
1.3.3 Thyroid
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Targeted Radionuclide Drug Market Perspective (2018-2029)
2.2 Targeted Radionuclide Drug Growth Trends by Region
2.2.1 Global Targeted Radionuclide Drug Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Targeted Radionuclide Drug Historic Market Size by Region (2018-2023)
2.2.3 Targeted Radionuclide Drug Forecasted Market Size by Region (2024-2029)
2.3 Targeted Radionuclide Drug Market Dynamics
2.3.1 Targeted Radionuclide Drug Industry Trends
2.3.2 Targeted Radionuclide Drug Market Drivers
2.3.3 Targeted Radionuclide Drug Market Challenges
2.3.4 Targeted Radionuclide Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Targeted Radionuclide Drug Players by Revenue
3.1.1 Global Top Targeted Radionuclide Drug Players by Revenue (2018-2023)
3.1.2 Global Targeted Radionuclide Drug Revenue Market Share by Players (2018-2023)
3.2 Global Targeted Radionuclide Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Targeted Radionuclide Drug Revenue
3.4 Global Targeted Radionuclide Drug Market Concentration Ratio
3.4.1 Global Targeted Radionuclide Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Targeted Radionuclide Drug Revenue in 2022
3.5 Targeted Radionuclide Drug Key Players Head office and Area Served
3.6 Key Players Targeted Radionuclide Drug Product Solution and Service
3.7 Date of Enter into Targeted Radionuclide Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Targeted Radionuclide Drug Breakdown Data by Type
4.1 Global Targeted Radionuclide Drug Historic Market Size by Type (2018-2023)
4.2 Global Targeted Radionuclide Drug Forecasted Market Size by Type (2024-2029)
5 Targeted Radionuclide Drug Breakdown Data by Application
5.1 Global Targeted Radionuclide Drug Historic Market Size by Application (2018-2023)
5.2 Global Targeted Radionuclide Drug Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Targeted Radionuclide Drug Market Size (2018-2029)
6.2 North America Targeted Radionuclide Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Targeted Radionuclide Drug Market Size by Country (2018-2023)
6.4 North America Targeted Radionuclide Drug Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Targeted Radionuclide Drug Market Size (2018-2029)
7.2 Europe Targeted Radionuclide Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Targeted Radionuclide Drug Market Size by Country (2018-2023)
7.4 Europe Targeted Radionuclide Drug Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Targeted Radionuclide Drug Market Size (2018-2029)
8.2 Asia-Pacific Targeted Radionuclide Drug Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Targeted Radionuclide Drug Market Size by Region (2018-2023)
8.4 Asia-Pacific Targeted Radionuclide Drug Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Targeted Radionuclide Drug Market Size (2018-2029)
9.2 Latin America Targeted Radionuclide Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Targeted Radionuclide Drug Market Size by Country (2018-2023)
9.4 Latin America Targeted Radionuclide Drug Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Targeted Radionuclide Drug Market Size (2018-2029)
10.2 Middle East & Africa Targeted Radionuclide Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Targeted Radionuclide Drug Market Size by Country (2018-2023)
10.4 Middle East & Africa Targeted Radionuclide Drug Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 POINT Biopharma
11.1.1 POINT Biopharma Company Detail
11.1.2 POINT Biopharma Business Overview
11.1.3 POINT Biopharma Targeted Radionuclide Drug Introduction
11.1.4 POINT Biopharma Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.1.5 POINT Biopharma Recent Development
11.2 Telix
11.2.1 Telix Company Detail
11.2.2 Telix Business Overview
11.2.3 Telix Targeted Radionuclide Drug Introduction
11.2.4 Telix Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.2.5 Telix Recent Development
11.3 ITM AG
11.3.1 ITM AG Company Detail
11.3.2 ITM AG Business Overview
11.3.3 ITM AG Targeted Radionuclide Drug Introduction
11.3.4 ITM AG Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.3.5 ITM AG Recent Development
11.4 Bayer AG
11.4.1 Bayer AG Company Detail
11.4.2 Bayer AG Business Overview
11.4.3 Bayer AG Targeted Radionuclide Drug Introduction
11.4.4 Bayer AG Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.4.5 Bayer AG Recent Development
11.5 Novartis
11.5.1 Novartis Company Detail
11.5.2 Novartis Business Overview
11.5.3 Novartis Targeted Radionuclide Drug Introduction
11.5.4 Novartis Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.5.5 Novartis Recent Development
11.6 Lantheus
11.6.1 Lantheus Company Detail
11.6.2 Lantheus Business Overview
11.6.3 Lantheus Targeted Radionuclide Drug Introduction
11.6.4 Lantheus Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.6.5 Lantheus Recent Development
11.7 Curium Pharma
11.7.1 Curium Pharma Company Detail
11.7.2 Curium Pharma Business Overview
11.7.3 Curium Pharma Targeted Radionuclide Drug Introduction
11.7.4 Curium Pharma Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.7.5 Curium Pharma Recent Development
11.8 Fusion Pharmaceuticals
11.8.1 Fusion Pharmaceuticals Company Detail
11.8.2 Fusion Pharmaceuticals Business Overview
11.8.3 Fusion Pharmaceuticals Targeted Radionuclide Drug Introduction
11.8.4 Fusion Pharmaceuticals Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.8.5 Fusion Pharmaceuticals Recent Development
11.9 RadioMedix, Inc.
11.9.1 RadioMedix, Inc. Company Detail
11.9.2 RadioMedix, Inc. Business Overview
11.9.3 RadioMedix, Inc. Targeted Radionuclide Drug Introduction
11.9.4 RadioMedix, Inc. Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.9.5 RadioMedix, Inc. Recent Development
11.10 Convergent Therapeutics
11.10.1 Convergent Therapeutics Company Detail
11.10.2 Convergent Therapeutics Business Overview
11.10.3 Convergent Therapeutics Targeted Radionuclide Drug Introduction
11.10.4 Convergent Therapeutics Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.10.5 Convergent Therapeutics Recent Development
11.11 IONETIX
11.11.1 IONETIX Company Detail
11.11.2 IONETIX Business Overview
11.11.3 IONETIX Targeted Radionuclide Drug Introduction
11.11.4 IONETIX Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.11.5 IONETIX Recent Development
11.12 Clarity Pharmaceuticals
11.12.1 Clarity Pharmaceuticals Company Detail
11.12.2 Clarity Pharmaceuticals Business Overview
11.12.3 Clarity Pharmaceuticals Targeted Radionuclide Drug Introduction
11.12.4 Clarity Pharmaceuticals Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.12.5 Clarity Pharmaceuticals Recent Development
11.13 RayzeBio, Inc
11.13.1 RayzeBio, Inc Company Detail
11.13.2 RayzeBio, Inc Business Overview
11.13.3 RayzeBio, Inc Targeted Radionuclide Drug Introduction
11.13.4 RayzeBio, Inc Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.13.5 RayzeBio, Inc Recent Development
11.14 AmbioPharm
11.14.1 AmbioPharm Company Detail
11.14.2 AmbioPharm Business Overview
11.14.3 AmbioPharm Targeted Radionuclide Drug Introduction
11.14.4 AmbioPharm Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.14.5 AmbioPharm Recent Development
11.15 Bracco Imaging
11.15.1 Bracco Imaging Company Detail
11.15.2 Bracco Imaging Business Overview
11.15.3 Bracco Imaging Targeted Radionuclide Drug Introduction
11.15.4 Bracco Imaging Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.15.5 Bracco Imaging Recent Development
11.16 Navidea
11.16.1 Navidea Company Detail
11.16.2 Navidea Business Overview
11.16.3 Navidea Targeted Radionuclide Drug Introduction
11.16.4 Navidea Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.16.5 Navidea Recent Development
11.17 China Isotope & Radiation Corporation
11.17.1 China Isotope & Radiation Corporation Company Detail
11.17.2 China Isotope & Radiation Corporation Business Overview
11.17.3 China Isotope & Radiation Corporation Targeted Radionuclide Drug Introduction
11.17.4 China Isotope & Radiation Corporation Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.17.5 China Isotope & Radiation Corporation Recent Development
11.18 Yantai Dongcheng
11.18.1 Yantai Dongcheng Company Detail
11.18.2 Yantai Dongcheng Business Overview
11.18.3 Yantai Dongcheng Targeted Radionuclide Drug Introduction
11.18.4 Yantai Dongcheng Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.18.5 Yantai Dongcheng Recent Development
11.19 Grand Pharma
11.19.1 Grand Pharma Company Detail
11.19.2 Grand Pharma Business Overview
11.19.3 Grand Pharma Targeted Radionuclide Drug Introduction
11.19.4 Grand Pharma Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.19.5 Grand Pharma Recent Development
11.20 Hengrui Medicine
11.20.1 Hengrui Medicine Company Detail
11.20.2 Hengrui Medicine Business Overview
11.20.3 Hengrui Medicine Targeted Radionuclide Drug Introduction
11.20.4 Hengrui Medicine Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.20.5 Hengrui Medicine Recent Development
11.21 Yunnan Baiyao Group
11.21.1 Yunnan Baiyao Group Company Detail
11.21.2 Yunnan Baiyao Group Business Overview
11.21.3 Yunnan Baiyao Group Targeted Radionuclide Drug Introduction
11.21.4 Yunnan Baiyao Group Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.21.5 Yunnan Baiyao Group Recent Development
11.22 SmartNuclide Biopharma
11.22.1 SmartNuclide Biopharma Company Detail
11.22.2 SmartNuclide Biopharma Business Overview
11.22.3 SmartNuclide Biopharma Targeted Radionuclide Drug Introduction
11.22.4 SmartNuclide Biopharma Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.22.5 SmartNuclide Biopharma Recent Development
11.23 Sinotau
11.23.1 Sinotau Company Detail
11.23.2 Sinotau Business Overview
11.23.3 Sinotau Targeted Radionuclide Drug Introduction
11.23.4 Sinotau Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.23.5 Sinotau Recent Development
11.24 Hexin Pharmaceutical
11.24.1 Hexin Pharmaceutical Company Detail
11.24.2 Hexin Pharmaceutical Business Overview
11.24.3 Hexin Pharmaceutical Targeted Radionuclide Drug Introduction
11.24.4 Hexin Pharmaceutical Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.24.5 Hexin Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
